Journal Article

DZNE-2025-01422

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png β-Blocker effects in huntington's disease: A caution on clinical interpretation.

Aziz, N. A. (First author)DZNE* ; Claassen, D. ; Petersén, Å. ; Weydt, P. (Last author)DZNE* ; Network, E. H. D. ; Group, H. S.

2025
IOS Press Amsterdam

This record in other databases:    

Please use a persistent id in citations: doi:10.1177/18796397251401745

Abstract: A recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. A prior Mendelian-randomization study found no causal link between β-blockers and HD onset; instead, genetically higher blood pressure was associated with later onset, raising concern that β-blockers' BP-lowering effects could be harmful. HD patients also have lower hypertension rates, and β-blockers carry risks such as depression and bradycardia. Given their heterogeneous mechanisms, rigorous experimental and clinical trials are needed before any clinical recommendations.

Keyword(s): bioethics ; biostatistics ; clinical care ; clinical trials ; ethics

---

Contributing Institute(s):

1. Clinical Research Coordination (Clinical Research (Bonn))
2. Population & Clinical Neuroepidemiology (AG Aziz)

Research Program(s):

1. 354 - Disease Prevention and Healthy Aging (POF4-354) (POF4-354)
2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Ebsco Academic Search ; Emerging Sources Citation Index ; IF < 5 ; JCR ; SCOPUS ; Web of Science Core Collection

---